Psoriasis Market – Plaque Psoriasis & Psoriatic Arthritis Therapeutics Research Report Now Available at ReportsnReports.com

ReportsnReports.com offers Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report in its store.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This
Market Research Reports and Industry Trends Analysis

Market Research Reports and Industry Trends Analysis

Dallas, TX (PRWEB) April 20, 2014

Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report says that over the last decades, therapeutic options for Plaque Psoriasis (PsO) and Psoriatic Arthritis (PsA) have expanded considerably and improved patients’ pain, function, and quality of life. Approved biologics fill in a critical unmet need of limited efficacy of DMARDs; however, as in most cases, one drug does not fit the bill for all the patients. The lack of targeted immune therapies other than TNF-α inhibitors in Psoriasis signals opportunities for drug developers to bring agents to market that offer treatment alternatives (Anti-IL-17, IL-13, JAK, PDE4 inhibitors, etc). Pfizer launched the first oral Rheumatoid Arthritis (RA) drug –Xeljanz (tofacitinib/ CP-690,550, JAK 1/3 inhibitor) in 2012 for pts with moderately to severely active RA who are inadequate responder or intolerant to Methotrexate (MTX) at a price almost at par with biologics. In the last couple of years, the face of healthcare has been changing due to challenges – quality and its affordability and accessibility to the providers and patients. The complete report is available at http://www.reportsnreports.com/reports/275192-therapeutic-class-overview-psoriasis-plaque-psoriasis-psoriatic-arthritis-novel-oral-drugs-and-biologics-to-change-future-treatment-paradigm.html.

This research believes there is an ample room for an efficacious affordable therapy to tap the mild to moderate RA pts population where biologics have not made a dent and expects few potential launches in 2014-15 (OTEZLA – apremilast, Xeljanz – tofacitinib) and onwards. This report highlights the novel targets – oral, injectables, and topical drugs in the pipeline for the treatment of Psoriasis, compares their clinical trials data, and their commercial potential.

Order a copy of Therapeutic Class Overview: Psoriasis – Plaque Psoriasis & Psoriatic Arthritis: Novel Oral drugs and Biologics to Change Future Treatment Paradigm market research report at http://www.reportsnreports.com/Purchase.aspx?name=275192.

List of tables provided in this report:

Approved/ Marketed Products
2 A. Psoriasis’ Pipeline: Small Molecules – Oral/ Injectable
B. Psoriasis’ Pipeline: Topical
3 Psoriasis’ Pipeline: Biologics
4 Select Late- & Mid-Stage Pipeline: Plaque Psoriasis
5 Select Late- & Mid-Stage Pipeline: Psoriatic Arthritis
6 Ixekizumab: Phase III Clinical Trial Designs
7 Brodalumab: Phase III Clinical Trial Designs
8 Clinical Data Comparison: Plaque Psoriasis – Biologics
9 A. Tofacitinib: PASI Improvement from Baseline
B. Tofacitinib: Improvement in Quality-of-Life (QOL) Measures
10 Other Targets in Clinical Development for RA
11 Genes Associated with Psoriasis Susceptibility
12 Competitive Landscape: Plaque Psoriasis
13 Competitive Landscape: Psoriatic Arthritis
1 PFE’s Xeljanz Launch vs. Other Recent RA Launches
2 The Structure and Function of the Cytokines IL-12 And IL-23
3 Clinical Data: ACCEPT – Head-To-Head Trial with Enbrel
4 MK-3222Neutralizes IL-23, Specically
5 Immunology and Immunotherapeutic Targets of Psoriasis
6 IL-17-Induced Signaling Pathways
7 Ixekizumab: Clinical Response (PASI And sPGA) @ week 20 17
8 Itolizumab Value Proposition with Marketed Products
9 Regulation of JAK–STAT Signaling
10 INCB39110: Response Rate - Exploratory Efficacy Analyses
11 ASP015K – Changes from Baseline in PASI at Day 42
12 PDE Inhibitors Crosstalk
13 AEB071 – PASI 75 Reductions Compared with Baseline
14 DRM02– Novel Mechanism of Action
15 DLX105 – PhIa Results (PASI Changes @ Day 14)
16 Psoriasis Treatment Ladder (Schematic)
17 US Psoriasis Market Estimation
18 Proposed Schema of the Evolution of A Psoriatic Lesion
19 Distribution of Psoriasis Severity
20 Use of Therapies Depending on the Disease Severity
21 Targeted Therapy Classication Based on Pathogenesis
22 Comparison of GRAPPA and AAD Treatment Guidelines

List of Figures

1 PFE’s Xeljanz Launch vs. Other Recent RA Launches
2 The Structure and Function of the Cytokines IL-12 And IL-23
3 Clinical Data: ACCEPT – Head-To-Head Trial with Enbrel
4 MK-3222Neutralizes IL-23, Specically
5 Immunology and Immunotherapeutic Targets of Psoriasis
6 IL-17-Induced Signaling Pathways
7 Ixekizumab: Clinical Response (PASI And sPGA) @ week 20 17
8 Itolizumab Value Proposition with Marketed Products
9 Regulation of JAK–STAT Signaling
10 INCB39110: Response Rate - Exploratory Efficacy Analyses
11 ASP015K – Changes from Baseline in PASI at Day 42
12 PDE Inhibitors Crosstalk
13 AEB071 – PASI 75 Reductions Compared with Baseline
14 DRM02– Novel Mechanism of Action
15 DLX105 – PhIa Results (PASI Changes @ Day 14)
16 Psoriasis Treatment Ladder (Schematic)
17 US Psoriasis Market Estimation
18 Proposed Schema of the Evolution of A Psoriatic Lesion
19 Distribution of Psoriasis Severity
20 Use of Therapies Depending on the Disease Severity
21 Targeted Therapy Classication Based on Pathogenesis
22 Comparison of GRAPPA and AAD Treatment Guidelines

Explore more reports on the pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ and other reports by MP Advisors at http://www.reportsnreports.com/publisher/mp-advisors/.

About Us:
ReportsnReports.com is an online market research reports library (http://www.reportsnreports.com/latest-market-research.aspx) of 400,000+ in-depth studies of over 5000 micro markets.


Contact

Follow us on: Contact's Google Plus